Ulcerative colitis

Understanding the differences between Crohn’s and ulcerative colitis helps patients and caregivers recognize likely symptom patterns, know which tests and treatments are commonly used, and when to seek specialist care....

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. The original article is from msn.com.

A new FDA approval means another biologic option for people with moderately to severely active Crohn’s disease, including patients who have failed or not tolerated prior therapies.

This announces a new FDA‑approved treatment (mirikizumab/Omvoh) for adults with moderately to severely active Crohn disease, offering another option for people who haven’t responded to prior therapies. The approval was...

A new FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderate-to-severe Crohn disease another treatment option with one-year trial data showing improved clinical remission and endoscopic healing versus...

An FDA approval means another biologic option is available for Crohn’s disease, which could affect treatment choices and insurance coverage. The approval also signals pharma competition and pipeline activity that may...

An FDA approval means Omvoh is now an available biologic option for adults with Crohn’s disease, potentially expanding treatment choices. Payer decisions mentioned in the article could affect how quickly patients can...

This gives adults with moderately to severely active Crohn’s disease an additional FDA-approved biologic option that targets the IL-23 pathway. Approval was supported by late-stage trial results showing improvements in...

A new FDA-approved treatment option is now available for adults with moderately to severely active Crohn’s disease, including people who’ve not responded to or tolerated prior therapies. Approval was supported by phase 3...

A new FDA-approved biologic option (Omvoh/mirikizumab) is now available for adults with moderately to severely active Crohn’s disease, potentially expanding treatment choices.

A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...

This provides a new FDA‑approved biologic option (mirikizumab/Omvoh) for adults with moderate–severe Crohn's disease, including people who did not respond to prior therapies. The approval was based on Phase 3 trial...

FDA approval means mirikizumab (Omvoh) is now an available biologic option in the US for adults with moderately to severely active Crohn’s disease, especially for people who did not respond to standard treatments. It may...

A newly FDA-approved biologic (Omvoh/mirikizumab) gives adults with moderately to severely active Crohn's disease another targeted treatment option. It's the same IL-23–targeting drug already approved for ulcerative...

A new FDA approval means an additional biologic treatment option for adults with moderate to severe Crohn's disease. This may affect treatment choices and insurance coverage discussions for people with IBD.

This expands U.S. treatment options: Omvoh (mirikizumab) is now FDA‑approved for both major forms of IBD (ulcerative colitis and Crohn's disease), which may matter for people who haven’t responded to other therapies. The...

At‑home tests that claim to identify food triggers for IBS or related gut conditions may influence how people manage symptoms. Patents covering tests for Crohn’s and ulcerative colitis suggest the company is aiming to...

Clinical trials expand treatment options and are how new IBD therapies are tested and approved. Low enrollment can delay access to future treatments for Crohn’s and ulcerative colitis.

Skin disease (hidradenitis suppurativa) may be more common in people with IBD—particularly Crohn disease—and could be linked with more severe intestinal complications. Awareness can prompt coordinated care between...

The review brings together evidence that genetics, immune responses, the gut microbiome, and environmental triggers interact to cause Crohn's disease and ulcerative colitis.

After a Crohn’s or UC flare you may tolerate less fiber and need easy-to-digest foods and extra protein to support recovery. This article gives practical, food-based suggestions to help with nutrient intake while your...

Fatigue is common in people with Crohn’s disease and ulcerative colitis and can persist even when standard measures say the disease is in remission. This study suggests stricter definitions of remission don’t necessarily...

This notes a new oral investigational drug (Amelenodor/NX-13) in Phase I for Crohn’s and ulcerative colitis and highlights industry predictions about its chances of advancing. People with IBD may want to know about...

Seeing well-known people talk about IBD or IBS can reduce stigma and show that these conditions affect many kinds of people, including athletes and performers. The article may help patients feel less alone and point to...